Drug Discovery and Development

At Incyte, our therapeutic focus spans Oncology and Inflammation & Autoimmunity. Since we began our drug discovery and development activities in early 2002, Incyte has grown into a global biopharmaceutical company with over 1,400 employees, including more than 600 world-class scientists who are leading the field of biopharmaceutical research.

In late 2011, we received our first U.S. Food and Drug Administration approval for Jakafi^® (ruxolitinib), a JAK1 and JAK2 inhibitor, and we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds through development. In addition to our marketed products we are advancing a diversified portfolio of clinical candidates, the majority of which were discovered by Incyte scientists.

Our exceptional team of drug discovery and development scientists is committed to finding solutions for some of the most critical unmet medical needs, and is led by distinguished executives with proven records of success and many scientific and clinical achievements.

Our strong discovery team is tightly integrated with all disciplines, including development, regulatory and commercial operations. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success.

Rigorous Science

Our scientific innovation is based on a proven competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. We have expanded our drug identification efforts to include small molecules, monoclonal antibodies and bispecific antibodies, providing us with the opportunity to explore combinations of therapies from both within and beyond our own portfolio.

We continually modify the resourcing of our discovery efforts to maximize information content when and where we need it and ensure that each program, regardless of stage, is executed in the most efficient and data-rich manner possible.